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Blinding in Physical Therapy Trials and
Its Association with Treatment Effects
A Meta-epidemiological Study
ABSTRACT
Armijo-Olivo S, Fuentes J, da Costa BR, Saltaji H, Ha C, Cummings GG:
Blinding in physical therapy trials and its association with treatment effects: a
meta-epidemiological study. Am J Phys Med Rehabil 2016;00:00Y00.
Objective: The aim of this study was to examine whether blinding of partici-
pants, assessors, health providers, and statisticians have an effect on treatment
effect estimates in physical therapy (PT) trials.
Design: This was a meta-epidemiological study. Randomized controlled trials in
PTwere identified by searching the Cochrane Database of Systematic Reviews for
meta-analyses of PT interventions. Assessments of blinding in PT trials were
conducted independently following established guidelines.
Results: Three hundred ninety-three trials and 43 meta-analyses that included
44,622 patients contributed to this study. Only a quarter of the trials were ade-
quately blinded (n = 80; 20%). Most individual components of blinding as well as
what they were blinded to were also poorly reported. Although trials with inap-
propriate blinding of assessors and participants tended to underestimate treatment
effects when compared with trials with appropriate blinding of assessors and
participants, the difference was not statistically significant (effect size, j0.07;
95% confidence interval, j0.22 to 0.08; effect size, j0.12; 95% confidence
interval, j0.30 to 0.06, respectively).
Conclusions: The lack of statistical significance between blinding and effect
sizes should not be interpreted as meaning that an impact of blinding on effect size
is not present in PT. More empirical evidence in a larger sample is needed to
determine which biases are likely to influence reported effect sizes of PT trials and
under which conditions.
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B linding has been acknowledged as an impor-
tant criterion for internal validity of randomized
controlled trials (RCTs). The purpose of blinding is
to prevent both performance bias associated with
patients_ and research team_s expectations and de-
tection bias to prevent bias by assessors.1,2 Because
the term blinding is used to describe blinding for
several components of a trial (i.e., subjects (partici-
pants), health care providers (therapists), data collec-
tors, outcome assessors, or data analysts), various
types of blinding can be used in a trial. In addition,
several blinding definitions for a trial can be done
based on how many components of the trial are
blinded (e.g., single, double, or triple blinded). How-
ever, these denominations have generated confusion
because they actually do not specify who is blinded and
mean different things to different people.3
Several meta-epidemiological studies investi-
gating associations between trial characteristics and
treatment effects have found that trials classified to
be not Bdouble blinded[ tended to overestimate
treatment effects.4Y8 Savovic et al.8 and Wood et al.,6
for example, found that the overestimation in trials
considered as Bnot double blinded[ was even more
pronounced for trials using subjective outcomes
such as patient-reported outcomes (pain, disability,
quality of life) by 23 to 25%. Nevertheless, other
meta-epidemiological studies found no significant
association between reported blinding and treat-
ment effects9Y14 or an underestimation of treatment
effects of trials with poor blinding.15
Overestimates or underestimates of treat-
ment effects, or bias, at the trial level, can lead to
biased or inaccurate results and conclusions in
systematic reviews and meta-analyses (MAs).6,16Y19
These factors can ultimately have repercussions on
clinical decision making and quality of patient care
because different assessments could lead to differ-
ent decisions for clinical practice.
Blinding in physical therapy (PT) and rehabil-
itation trials is particularly laborious when compared
with other fields of medicine.20,21 The most com-
monly used control groups in PT trials include in-
terventions as simple as nonparticipation (waiting
list), usual care, or another intervention. These control
interventions are associated with nonspecific physio-
logic effects that can affect the active intervention,
especially when patients and care providers are not
blinded to interventions.21 Because of the nature of
PT interventions (e.g., exercises, devices, manual
therapy), blinding for therapists and patients may
be challenging and even impossible.22 Indeed,
blinding for health care providers, patients, and
outcome assessors is less frequently reported in trials
involving nonpharmacological interventions.23 Al-
though progress in reporting blinding in PT and re-
habilitation trials has been certainly documented in
the last decade,21 this is still incomplete and does not
fulfill current recommendations.21
In addition, the type of outcome is crucial when
evaluating blinding. Objective and automated out-
comes (i.e., mortality, laboratory results, and admin-
istrative data) may be less prone to assessment bias
than subjective outcomes such as pain, which is a self-
reported measure and commonly used in PT.6 There-
fore, trials evaluating effects of PT treatments such as
on mortality or hospitalizations (automated data
obtained from administrative hospital databases) may
be less susceptible to bias than trials evaluating effects
of PT treatments on pain or self-reported measures.
However, this theoretical thinking needs to be proven
based on empirical evidence in the PT field.
Most of the empirical evidence regarding as-
sociations between blinding and treatment effect
estimates comes from RCTs in medicine and is based
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mainly on dichotomous outcomes and looking only at
limited aspects of blinding (i.e., double blinding).6,7,15
The closest meta-epidemiological study to PT area was
performed in trials of osteoarthritis investigating sev-
eral types of treatments such as drug trials and other
nonpharmacological interventions.5 No such com-
parative studies using continuous outcomes have been
conducted in other health areas such as the allied
health professions, including PT.
According to recent meta-epidemiological stud-
ies,2,8 the effect of blinding is highly unpredictable, and
separate analyses of blinding effects in individual trials
and MAs for performance (blinding of participants and
personnel) and detection biases (blinding of asses-
sors) are needed. Therefore, empirical evidence is
needed in PT to determine the extent to which
blinding and forms of blinding affect treatment effect
estimates. This information will support develop-
ment of future guidelines for designing, conducting,
implementing PT trials, and assessing quality/risk of
bias of PT trials in systematic reviews and MAs and
ultimately the strength of evidence for application in
clinical decision making.
Our objectives were to (1) describe use of
different forms of blinding; (2) determine appro-
priateness of its reporting in PT RCTs; (3) examine
whether blinding of participants, assessors, health
providers, and statistician has an effect on treat-
ment estimates in PT trials; and (4) determine if
these effects differ depending on characteristics of
the MAs analyzed, such as magnitude of effect size
(ES), MA heterogeneity, type of outcome (subjective
or objective), and whether the MA involves the
musculoskeletal area.
METHODS
This study is part of a largemeta-epidemiological
project investigating the association between biases
and treatment effect estimates in PT trials. The pro-
tocol for this meta-epidemiological study was pub-
lished previously.24
Study Selection
The Cochrane Database of Systematic Reviews
was systematically searched from 2005 to May 25,
2011, for MAs of PT interventions using the fol-
lowing words: PT or physiotherapy, rehabilitation,
exercise, electrophysical agents, acupuncture, mas-
sage, transcutaneous electrical stimulation, interfer-
ential current, ultrasound, stretching, chest therapy,
pulmonary rehabilitation, manipulative therapy, mo-
bilization, and related terms. Details of the search
strategy can be found elsewhere.25 Meta-analyses and
their RCTswere included if (1) theMA included at least
3 RCTs comparing at least 2 interventions, with at
least one of the interventions being currently or
potentially part of PT practice according to the
World Confederation for Physical Therapy26; (2) the
outcome of interest in the MA (main outcome or
with the largest number of trials) was continuous.
We decided to use continuous outcomes for this
project for 2 reasons: (1) to extend the knowledge
base of meta-epidemiological studies to continuous
outcomes because most available evidence from
these studies has been modeled on dichotomous
outcomes such as all-cause mortality and presence
of events.4,6Y10,12,13,15,16,27Y29; and (2) continuous
outcomes, such as pain, disability, and range of
motion, are commonly used in PT trials, which
makes our information more applicable to practice.
A unique code generated by the Reference Man-
ager bibliographic program was assigned to each MA
and trial that met the inclusion criteria. This code
was used to randomly select studies to be analyzed
and also to randomize the order of evaluation. The
first author (SA-O) randomly selected each MA to
be included and accompanying trials by drawing
the code of the selected MA first and then the se-
lected trial from an opaque envelope. This process
ensured that the researcher had no influence on
the studies selected or the order of evaluation.
Assessment of Blinding Domains
We evaluated specific forms of blinding for each
trial component such as participants (i.e., blinding of
individuals who are randomly assigned to interventions
under evaluation), assessors (blinding of individuals
who collect data for trial outcomes), therapists
(blinding of clinicians, i.e., physiotherapists or other
care providers who care for participants during the
trial), statistician (blinding of individuals who con-
duct trial analyses), and investigators (blinding of
individuals who are nominated as trial principal in-
vestigators), and overall appropriateness of blinding
(whether the appropriate component of blinding
[participants, assessors, or irrelevant] based on the
main outcome of interest) was used as suggested in
the most commonly used tools used in PT (i.e., Del-
phi List, PEDro, Maastricht, Maastricht-Amsterdam
List, Bizzini, van Tulder and Jadad tools).30 A 3-point
scale (yes, no, unclear) was used to assess items,
and guidelines for scoring were extracted from the
guidelines of these tools.
Furthermore, we evaluated whether each indi-
vidual component of a trial would be blinded to (1)
study hypothesis, (2) details of interventions, (3)
random assignment, (4) outcome measures, and (5)
outcome analysis. In addition, we evaluated whether
www.ajpmr.com Blinding in Physical Therapy Trials 3
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blinding was successful (whether the blinding was
maintained in the trial and the participants/assessors/
personnel did not guess the random allocation) as
suggested by Friedberg et al.31We based the assessment
of blinding on the main outcome described in the MAs.
Data Extraction of Treatment Estimates
and Trial Characteristics
Two independent reviewers extracted (any of
these reviewers: SA-O, JF, HS, CH, AC, DP) data
from each trial based on each MA. Data on means,
SDs, sample sizes, type of interventions (and their
details such as intensity, frequency, and dosage),
information related to type of outcome (i.e., ob-
jective, subjective), funding source, publication
year, design characteristics, and statistical analysis
were extracted. The outcome of interest selected for
each MA in the Cochrane review that met the eli-
gibility criteria was chosen as the primary outcome
for analysis. If not clearly specified, the outcome
was determined according to the MA that contained
the largest number of trials in the review.
Characteristics of the Reviewers_ Panel
Six reviewers with experience in different areas
of health sciences research comprised the review
panel for this study. Characteristics of the review
panel can be found elsewhere or upon request.25,32,33
Analysis
Data Synthesis
We carefully followed the same methodology to
perform meta-epidemiological analysis described in
predominant studies in this field.5Y8,12Y16,27,34,35 In
order to determine whether forms of blinding affect
treatment effect estimates, a 2-level analysis was
conducted using a metaYmeta-analytic approach
with a random-effects model to allow for within and
between MAs heterogeneity as described by Sterne
et al.27 The first-level analysis (within MA) was as
follows: we derived ESs for each trial by dividing
the between-group difference in mean values by the
pooled SD as described by Cohen.36 A negative ES
indicates a beneficial effect of the experimental in-
tervention. If some required data were unavailable,
we used approximations as previously described.37
Data from each trial were obtained from each MA.
We followed the Cochrane reviews to determine the
comparison included for analysis (i.e., treatment of
interest and control group). In the case of studies
appearing in more than 1 review, the study was
considered only once in the MA with the fewer
number of overall studies. We then calculated 2
pooled ES for each MA: one corresponding to the
pooled ES from those studies having the character-
istic of interest (e.g., blinding assessment) and the
other for those studies that did not (e.g., no or
unclear blinding assessment). We used standard
random-effects MAs to combine ES across trials and
calculated the DerSimonian and Laird estimate of the
variance to determine heterogeneity between tri-
als.5,34 Then, for each MA, we derived the difference
between pooled ES estimates from trials with and
without the characteristic of interest (e.g., blinding of
assessor). A negative difference in ES indicates that
trials with the characteristic of interest show a more
beneficial effect for the experimental group.
The second-level analysis (between MAs) in-
volved pooling the results of the previous analysis
to describe the effect of each trial component across
all MAs. The ESs were also combined at this stage
using the DerSimonian and Laird random-effects
models38 to allow for between-MA heterogeneity.
Formal tests of interaction between adequate
blinding component and estimated treatment ben-
efits were performed separately for each MA based
on Z scores using the estimated difference in ES
between trials with and without adequate blinding.
We additionally stratified analyses accompanied
by interaction test based on Z scores according to
prespecified characteristics: treatment benefit in
overall MA: small (ES 9j0.5) versus large (ES
ej0.5); between-trial heterogeneity in overall MA
(low [T2 G 0.06] vs. high [T2 Q 0.06]), nature of
outcome (subjective or objective), and if the inter-
vention was classified as musculoskeletal or other
PT area. The prespecified cutoff of T2 = 0.06 cor-
responds to a difference between the smallest and
largest ES of approximately 1 ES.
In order to evaluate the effect of different types
of blinding on treatment effect estimates, we limited
analyses to studies describing a true control group
(i.e., group receiving no treatment or a waiting list)
or placebo intervention and studies in which the
direction of expected treatment effect was evident
(i.e., standard care vs. standard care plus active in-
tervention; and active intervention 1 plus active
intervention 2 vs. active intervention 1). Again, a
DerSimonian and Laird random-effects model was
used to pool data. Stata statistical software version
12 (StataCorp LP, College Station, TX) was used to
perform these analyses.
RESULTS
Selection and Characteristics of MAs
and RCTs
The search identified 3901 Cochrane reviews,
with 271 reviews potentially relevant to PT. Of
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these, 68 reviews included an MA of at least
3 studies of PT interventions and examined at least
1 continuous outcome. We randomly selected
44 MAs but excluded one39 because it used follow-up
data from the same group rather than a control group
for comparison (Fig. 1). Forty-three MAs including
393 trials and analyzing 44,622 patients contributed
to this study. Table 1 summarizes the characteristics
of the 43 Cochrane reviews. Briefly, reviews were
published between 2008 and 2011 and included MAs
of the effectiveness of PT interventions for mus-
culoskeletal (22 reviews),40Y48 cardiorespiratory
(9 reviews),49Y57 neurological (6 reviews),58Y64 and
other PT areas (6 reviews).64Y69 Most trials were
parallel-group trials (367; 93.4%) and single-center
studies (298; 76%) and had active control in-
terventions (362; 92%). The most common inter-
vention was exercise (n = 282; 71.8%). Remaining
trials used a combination of exercise and physical
agents, manual therapy, and other treatments such
FIGURE 1 Diagram for identification of studies.
TABLE 1 Characteristics of the selected MA within PT areas
Musculoskeletal Cardiorespiratory Neurology Other
Characteristics
No. of MAs 22 9 6 6
Median year of publication 2009 2010 2009 2009
Total no. of trials included 194 78 52 69
Total no. of patients included 19861 9015 2138 13608
Main intervention
Exercise 13 7 3 5
Physical agents 1 0 1 0
Acupuncture 2 0 0 0
Manual therapy 1 0 0 0
Other 1 2 2 1
Outcomes
Clinician-assessed outcome 8 4 6 3
Self-reported outcome 11 4 0 2
Administrative data or automated outcome 3 1 0 1
www.ajpmr.com Blinding in Physical Therapy Trials 5
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as respiratory exercises. Supplementary Table S1
(Appendix 1; http://links.lww.com/PHM/A245) lists
characteristics of the 43 MAs.
Reporting of Blinding
Details of reporting of blinding by participants,
assessors, investigators, therapists, and statisticians
and what they were blinded to (hypothesis, details of
intervention, random assignment, and analysis) can
be found in Table 2. General description of blinding
for each component is as follows.
Blinding of Participants
Blinding of participants to random allocation
was used in only 31 (7.9%) of 393 trials. The
remaining trials either did not blind participants
(n = 88; 22.4%) or were unclear whether partici-
pants were blinded (n = 272). Participants were
reported as blinded to the study hypothesis in
20 trials (5.1%). In addition, only a small number of
trials (n = 13; 3.3%) reported that participants were
blinded to intervention details, whereas the vast
majority of them (n = 379; 96.4%) did not blind
subjects to intervention details (n = 313). Only 7%
of trials (n = 27) blinded participants to outcome
assessment. None of the trials reported that they
kept participants unaware of data analysis. Only 4
trials reported that blinding was successful, and
5 reported that it was not. The rest of the trials did not
report evaluation of participants_ blinding (Table 2).
Blinding of Assessors
Of 393 trials, blinding of outcome assessors to
random allocation was used in 95 trials (24%). As-
sessors were reported blinded to the study hypoth-
esis in only 13 trials (3.3%). In addition, 41 trials
(10.4%) reported that assessors were blinded to
intervention details. None of the trials reported that
they kept assessors unaware of data analysis. Only 6
trials (1.5%) reported that blinding of assessors was
successful. The rest of the trials did not report, or it
was unclear if they evaluated the success of
assessors_ blinding (Table 2).
Blinding of Investigators
Of 393 trials, blinding of investigators to ran-
dom allocationwas reported in 13 trials (3.3%). Trials
did not report whether investigators were blinded to
statistical analysis. In addition, none of the trials
reported whether blinding of investigators was suc-
cessful. Only 2 trials (n = 0.5%) reported to blind
principal investigators to outcome measures.
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Remaining trials either did not report that princi-
pal investigators were blinded to outcome mea-
sures (n = 387; 98.5%) or clearly stated that they
did not blind principal investigators to outcome
measures (n = 4; 1%). None of the trials in this
category reported blinding of study hypothesis and
intervention details. However, principal in-
vestigators are aware of these features because they
are designing and planning the trials (Table 2).
Blinding of Therapists
A minimal percentage of trials (only 2 trials
[0.5%]) reported blinding of therapists. Remaining
trials did not blind therapists because this was not
possible (n = 391; 99.5%). Therapists were re-
ported blinded to the study hypothesis in only 1 trial
(0.3%). Only 3% of trials (n = 12) blinded therapists
to outcome assessments. None of the trials reported
keeping therapists unaware of data analysis. None of
the trials reported whether blinding of therapists was
successful (Table 2).
Blinding of Statisticians
Blinding of statisticians to random allocation
was reported in only 15 trials (3.8%). Remaining
trials either did not blind the statistician (n = 3;
0.8%) or were unclear whether statisticians were
blinded or not (n = 375; 95.42%). Trials did not
report whether statisticians were blinded to study
hypothesis and intervention details. None of the
trials reported that statisticians were blinded to
outcome measures as well. None of the trials
reported whether blinding of the statistician was
successful (Table 2).
Double Blinding
Of 393 trials, only 10 trials were reported to be
double blinded (2.54%). The definition of double
blind varied. Some trials defined double blind when
both participants and investigators were blinded.
Another trial was reported as double blinded when
participants, assessors, data managers, and stat-
isticians were blinded. Another trial was stated to
be double blinded, but only specified participants
as blinded. Remaining trials (n = 7) defined double
blinding as participants and assessors being blinded.
Overall Blinding Adequacy
Of 393 trials, 80 were considered as having
appropriate blinding (20.4%). Remaining trials ei-
ther were considered to have no appropriate blinding
(n = 42; 10.7%) or were unclear whether they had
appropriate blinding (n = 271; 69%).
Blinding of Participants and Treatment
Effects in PT Trials
To analyze the effect of blinding of assessors on
treatment effects, 9 MAs including 121 trials and
analyzing 13,151 patients were used. Figure 2
shows the forest plot of differences in ESs between
trials with adequate and inadequate blinding of
participants. Although trials with inappropriate
blinding of participants tended to underestimate
treatment effects when compared with trials with
appropriate blinding of assessors, the difference
was nonYstatistically significant (ES, j0.12; 95%
confidence interval [CI], j0.30 to 0.06). Results of
stratified analyses are displayed in Figure 3. In this
FIGURE 2 Forest plot of the differences in ESs between trials with and without appropriate blinding
of participants.
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stratified analyses, none of the MA characteristics
had a statistically significant interaction.
Blinding of Assessors and Treatment
Effects in PT Trials
Seventeen MAs including 165 trials and ana-
lyzing 23,316 patients were used to analyze the
effect of blinding of assessors on treatment effects.
Figure 4 shows the forest plot of the differences in
ESs between trials with adequate and inadequate
blinding of assessors. Although trials with inap-
propriate blinding of assessors tended to underes-
timate treatment effects when compared with trials
with appropriate blinding of assessors, the difference
FIGURE 3 Forest plot of the differences in ESs between trials with and without appropriate blinding of participants
stratified by MA characteristics (ES magnitude, heterogeneity, type outcome, and PT area).
FIGURE 4 Forest plot of the differences in ESs between trials with and without appropriate blinding of assessors.
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was nonYstatistically significant (ES, j0.07; 95%
CI, j0.22 to 0.08). None of the MA characteristics
had a statistically significant interaction.
Blinding of Investigators and Treatment
Effects in PT Trials
To analyze the effect of blinding of investigators
on treatment effects, 7 MAs including 113 trials and
analyzing 10,854 patients contributed to this analy-
sis. Trials with inappropriate blinding of investigators
tended to have an overestimated treatment effect
when compared with trials with appropriate
blinding of investigators, although the difference
was nonYstatistically significant (ES, 0.10; 95% CI,
j0.17 to 0.38). None of the MA characteristics
had a statistically significant interaction.
Blinding of Statistician and Treatment
Effects in PT Trials
Six MAs including 89 trials and analyzing
11,363 patients contributed to the analysis of the
effect of blinding of investigators on treatment effects.
These results showed that the difference between
trials with inappropriate blinding of statistician and
trials with appropriate blinding of statistician was
nonYstatistically significant (ES, 0.04; 95% CI,
j0.18 to 0.27). None of the MA characteristics had
a statistically significant interaction.
Overall Adequacy of Blinding and
Treatment Effects in PT Trials
For the purpose of analyzing the overall effect
of adequacy of blinding on treatment effects, 16 MAs
including 182 trials and analyzing 16,019 patients
contributed to this analysis. Although trials with
inappropriate overall blinding tended to underesti-
mate treatment effects when compared with trials
with appropriate overall blinding, the difference was
nonYstatistically significant (ES, j0.08; 95% CI,
j0.28 to 0.12). None of the MA characteristics had a
statistically significant interaction.
DISCUSSION
The results of this study showed that reporting
and conducting blinding in PT are poor. Only a
quarter of trials were adequately blinded. Remaining
trials were considered either unclear (69%) or not
appropriately blinded (11%). Most individual com-
ponents of blinding (e.g., participants, assessors,
statisticians, and investigators) and what they were
blinded to (hypothesis, details of intervention,
random assignment, analysis, etc.) were also poorly
reported. Results of our meta-epidemiological ap-
proach show that trials with inadequate blinding of
assessor, participant, and overall appropriateness of
blinding tended to underestimate treatment ef-
fects, although differences were not statistically
significant.
Underreporting and Difficulty of Blinding
in PT Trials
Of note, it is important to highlight that a large
percentage of trials did not clearly report if blinding
was accomplished or not for different components
of the trial. The large amount of underreporting of
blinding in trial reports has been previously reported,
especially for nonpharmacological trials.20,23 Although
reporting of methodological factors in physical medi-
cine, rehabilitation,21 and PT70 has improved in recent
years,21 reporting of blinding and specifically blinding
of participants has not increased at all, and re-
porting of blinding of therapists has actually de-
creased every year according to a recent report.70 In
addition, Moseley et al.70 found that reporting of
blinding of assessors has not increased as much as
other methodological items, with only a 3.4% of
increase reporting by year.70 Thus, it seems that
adequate reporting of blinding is lacking in reha-
bilitation, especially in PT trials. Boutron et al.71
highlighted that lack of blinding and its under-
reporting could be due to lack of awareness of
available and innovative methods for blinding
in nonpharmacological trials. Thus, we have
compiled a table with possible ways to enhance
blinding in the PT and related fields (see Appendix
2; http://links.lww.com/PHM/A246).
In addition, poor reporting has been linked to
blinding being harder to perform in nonpharma-
cological trials such as PT trials.20 Only 22% of trials
assessing rehabilitation, acupuncture, education, and
spa therapy were judged as possible to blind patients in
an earlier report.20 Perceived risk of not blinding was
more often considered Bmoderate[ or Bimportant[ in
nonpharmacological trials than pharmacological trials
for patients and outcome assessors, thus introducing
biases to study results.20 Although these examples
are not exhaustive, it can provide researchers work-
ing in PT and rehabilitation with some guidance on
how to blind certain components of the trials to avoid
performance or detection biases.
Most examples applicable to rehabilitation trials
could produce a placebo effect when using physical
agents_ therapies or when applying acupuncture, al-
though this requires innovative solutions to make
it credible. For example, recent systematic reviews
highlighted that new types of needles can be used to
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produce effective and credible placebos for acu-
puncture,72 especially one known as the BTakakura
device,[ which shows promising results to blind
both participants and therapists.73 In addition,
some studies have used naive participants to certain
PT treatments such as transcutaneous electrical
stimulation or interferential current to make a pla-
cebo treatment credible.74 However, when using an
attention-control group or other active (supposedly
non therapeutic) interventions such as hands-on
procedures without adjustments or manipulation,
blinding of participants is challenging because the
generation of a credible placebo controlled trial in
these circumstances is generally not possible or
cumbersome.22 One solution would be to blind partic-
ipants, assessors, statisticians, or other personnel to
trial hypothesis and purposes. In this way, performance
biases could be reduced; however, it comes with ethical
considerations. Furthermore, when possible, objec-
tive outcomes or outcomes that can be measured
by an external blinded assessor or panel are used as
suggested by the use of the PROBE (Prospective
Randomised Open Blinded Endpoint) design.75
However, this type of design is limited when the
main outcome is a patient-reported outcome.
Other possible strategies to decrease the pos-
sibility for biases, especially at the therapist level,
would be expertise-based RCTs.76 Therapists par-
ticipating in trials of competing interventions (e.g.,
manipulation vs. acupuncture) usually have their
own preconceived opinion about which treatment
will be more effective and are likely to believe that
the type of treatment they practice and have expertise
in will be more effective. As a result of unblinding
therapists, it is very unlikely that 1 clinician will
maintain clinical equipoise when using 2 compet-
ing treatments. Generally, they could be biased
to perform one treatment better than the other,
and they could potentially prescribe differential
cointerventions to study groups. Furthermore, if
therapists are also data collectors of main outcomes
in the trial, they may differentially record data or
interpret outcomes depending on whether patients
received the form of therapy that they practice.
Thus, using expertise-based RCTs would minimize
differential-expertise bias by allocating participants
to clinicians with expertise in the specific inter-
ventions under investigation who are committed to
performing either intervention A or intervention B
based on their expertise. This randomization would
also increase fidelity of the intervention.
It should be noted that when evaluating the
influence of blinding on treatment effects, other
confounding factors, such as participant expectation/
experience and practitioner-participant interac-
tion, may affect the therapeutic effect.74 In our set
of analyzed trials, the majority of included studies
failed to report on whether these issues were con-
sidered and what precautions were taken. Future
RCTs should report more details on how much
information was given to participants regarding the
interventions and how therapists-participant in-
teractions were managed (limited or encouraged).
Another method proposed to prevent perfor-
mance bias is using the so-called BZelen[ randomi-
zation method. According to a review,77 the Zelen
method was commonly used to limit bias, especially to
avoid Bresentful demoralization (i.e., disappointment
by not getting the alternative treatment, which affects
response to treatment and study outcomes) and the
Hawthorne effect (i.e., a change in behavior occurring
because of trial participation rather than any treat-
ment) generally occurring in conventional RCTs.
When using the Zelen method, the patients in the
control group are not aware of the presence of an al-
ternative therapy; thus, resentful demoralization could
be reduced and could also potentially decrease the
dropout rate, reporting of adverse events, and nega-
tive results, whichhas been commonly acknowledged
in conventional RCTs.78 One of the drawbacks of the
Zelen design is the presence of crossovers, which will
dilute the treatment effect in trials using this type of
design. In addition, the Zelen method has been crit-
icized ethically because of lack of consent.
Blinding: Reporting and Conduct
It is possible that authors do not report
blinding in their articles, but they do perform ad-
equate blinding in their actual trials. Devereaux et
al.79 found that authors fail to report in their arti-
cles blinding status of participants in 26%, health
care providers in 64%, data collectors in 84%,
outcome assessors in 83%, and data analysts in 96%
of them. Nevertheless, trials that were not reported
to be blinded actually used blinding in 20%, 65%,
65%, 79%, and 50% of participants, health care
providers, data collectors, outcome assessors, and
data analysts, respectively.79 Thus, it is possible
that lack of reporting does not necessarily mean
poor conduct. However, Devereaux et al.79 analyzed
a subset of studies (n = 98) in the area of internal
medicine, and thus, this information might not be
applicable to PT and rehabilitation areas.
Because the term blinding is used to describe
blinding for several components of a trial, a lot of
confusion exists in describing who is really blinded.
The term double blinding may refer to blinding 2 of
the components of a trial and any combination of
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them, for example, participants and health care
providers, investigators and data collectors, and
assessors and data analysts. Thus, the definitions of
single, double, or triple blinded vary depending on
who is making the judgment, which makes the use
of these descriptions confusing and ineffective. This
was evidenced in the results of our study because
several combinations were used to describe double
blinding. In order to avoid confusion, the Consoli-
dated Standards of Reporting Trials (CONSORT)
Statement recommends discard the terms single,
double, or triple blinding. Instead, the CONSORT
statement suggested that authors report detailed
blinding-related parameters, including who was
blinded and how, and explain the mechanisms of
blinding and reasons if any key trial collaborator is
not blinded.80 Also, the CONSORT statement rec-
ommends avoiding the assessment of the success of
blinding because of lack of empirical evidence and
validity supporting its practice.81 In addition to
recommendations provided by the CONSORT state-
ment, and based on the results of this study, we
recommend that authors of primary RCTs report
which components of the trial people were blinded to
(e.g., hypothesis, details of intervention, random as-
signment, outcome assessment, analysis) and the
implications of blinding or lack of blinding in
study results. In this way, it is easier to evaluate
the influence of these biases in the trial_s results.
For example, if the main outcome of a trial is self-
reported and participants were not blinded to
random allocation, blinding participants to study
hypotheses could minimize performance biases,
and thus, results of the study could be viewed as
less biased than only having the information of not
being blinded. Journal editors and reviewers have
an essential role in this aspect. They should make
sure that a clear description of each of the com-
ponents of blinding is performed. This will ensure
that the quality of reporting of future trials is
improved and that the evaluation of the risk of bias
of RCTs in this field is more accurate.
The Relationship Between Blinding and
Treatment Effect Estimates
Lack of blinding in RCTs has been associated
with increased magnitudes of observed treatment
effects.4Y6,8 Some meta-epidemiological studies have
found that lack of double blinding may overestimate
treatment effects by 9% to 44%4Y6,8 Nevertheless,
other meta-epidemiological studies found no sig-
nificant association or underestimation of treat-
ment effects in trials with inappropriate blinding of
patients, therapists, and outcome assessors.9Y11,14,15
The results of the present study are in agreement with
these reports. There was no statistically significant
difference between trials with and without appropri-
ate blinding of participants, assessors, investigators,
or statisticians or overall blinding on treatment effects.
Most of the previous reports have wide CIs around
the estimates, which does not rule out the possible
overestimation or underestimation of effects overall.
This is in line with the results of the present study,
which is also characterized by wide CIs. In addition,
the direction of bias for blindinghas been inconsistent.
As opposed to the general finding of overestimation of
treatment effect for trials of poor quality, this study
shows that trials with inappropriate blinding tended
to show a decreased effect when compared with trials
with adequate blinding. A recent report12 suggested
that results for meta-epidemiological studies in-
vestigating evidence of bias and treatment effect
estimates varied between meta-epidemiological data
sets, individual MAs within data sets, and clinical
fields. Thus, the direction of the bias is not con-
sistent for all areas of research, andmore research is
needed to provide more insights regarding the direc-
tion of the biases.2,8
In addition, with lack of reporting of blinding,
nonsignificant results obtained by this study may be
related to insufficient power to detect differences
because few trials reported appropriate blinding.
Therefore, lack of reporting greatly hindered our
ability to conclude, and thus, the influence of blinding
on treatment effect estimates for this area is still
unknown. Editors and reviewers can reinforce good
reporting practice by following CONSORT guidelines
and recommendations reported here to achieve good
reporting of methodological indicators, so that
accurate information can be extracted from trial
reports. This is a crucial step to advance the field.
In addition, heterogeneity of the data set could
be another factor that could explain in part the results
of this study. According to Hempel,12 when studies
differ in risk of bias, it is likely that they also differ
in other ways, both measured and unmeasured,
which also might affect the ES found in the study.
According to Devereaux et al.,79 poor reporting of
trials may have acted as a Bmarker[ for other bias and
may explain in part the heterogeneity seen in the
meta-epidemiological studies investigating the asso-
ciation between biases and treatment effect estimates.
The research field of risk of bias assessment has
been controversial. The meta-epidemiological studies_
methodologies are in constant development, and
thus, the failure to detect a statistically significant
association between blinding and ES should not be
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interpreted as meaning that an effect is not present.
More empirical evidence is needed to determine
which biases (methodological quality factors) are
likely to influence reported ES and under which
conditions. This information will be crucial for the
field of knowledge synthesis, especially for researchers
and consumers of systematic reviews when deter-
mining the validity of the existing evidence.
Strengths and Limitations
As far as our knowledge, this is the first study in
PT that has exclusively and exhaustively evaluated
individual components of blinding (e.g., partici-
pants, assessors, statisticians, and investigators), as
well as to what they were blinded to (hypothesis,
details of intervention, random assignment, analysis,
etc.). In addition, this is the first meta-epidemiological
study conducted in PT evaluating the influence of
blinding on treatment effects.
Our study assessed only published reports and
not actual trials. We did not contact the authors of
the actual trials because contacting authors is time
consuming, inconvenient, unpractical, and poten-
tially costly, which limits the feasibility of this ap-
proach every time that a risk of bias assessment is
conducted. We decided to analyze reports with the
information provided by the authors, which is the
most common way that evidence syntheses are
performed and reflect a pragmatic approach to risk
of bias assessments.
The lack of reporting of different types of
blinding precluded conducting sensitivity analysis
and also having enough power to find a difference
when this could exist. We could not perform sen-
sitivity analyses for blinding to study hypothesis,
details of interventions, outcome measures, and
outcome analysis. In addition, evaluation of the
success of blinding was also not well reported, and
thus, it was impossible to perform further analyses.
Evaluation of the success of blinding in clinical
trials has been extensively debated because it does
not actually evaluate the success of blinding.82 The
implication of guessing allocation is not the same
as that of knowing allocation.
CONCLUSIONS
Reporting and possibly conduct of blinding in
PT trials were found to be poor. In addition, trials
with inadequate blinding of assessor and partici-
pant and overall appropriateness of blinding tended
to underestimate treatment effects, although the
differences were not statistically significant. The lack
of statistical significance between blinding and ES
should not be interpreted as that an effect is not
present. More empirical evidence is needed to deter-
mine which biases (methodological quality factors)
are likely to influence reported ES and under which
conditions. This information will be crucial for
the field of knowledge synthesis, especially for re-
searchers and consumers of systematic reviews when
aiming to summarize the existing evidence appro-
priately. Researchers should look for creative solu-
tions to avoid performance and detection bias when
possible. In addition, researchers and journal editors
should adhere to the CONSORT statement to mini-
mize the poor reporting of biases to facilitate the
research in this field. Clinicians implementing re-
search into practice should pay attention to perfor-
mance and detection biases due to lack of blinding
when reading and interpreting the results of RCTs
in PT area because these biases could alter the ac-
curacy of the treatment effects.
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